Prof. Stefano Pallanti - CV 18 Agosto 2022

1. CURRICULUM VITAE STEFANO PALLANTI, M.D. PhD H-index: 60 (as of April 2022) EDUCATION December 1983 Medical Doctorate Degree (M.D.) and European Medical License, 6-year course, final dissertation thesis “Life events and Depression” University of Florence, School of Medicine, Florence, Italy November 1987 Residency In Psychiatry, 4-year course, final dissertation thesis “Life Events and Schizophrenia” University of Florence, School of Medicine, Florence, Italy November 1988 Residency in NeuroPhysiopathology admitted to the second year. University of Florence, School of Medicine, Florence, Italy June 1993 Ph.D in Neurophysiopathology, 4-year course, final dissertation thesis “Contingent Negative Variation in Normal Elderly Population “ University of Florence, School of Medicine, Florence, Italy May 2013 Certificate of Deep TMS Operation, completed by Brainsway Inc., Israel May 2018 Certificate of completion of Electroconvulsive Therapy Training, completed by Villa Baruzziana, Ospedale privato accreditato Neuropsichiatrco, Bologna, Italy MEDICAL LICENSES Italian Licence to Practice, Registration at the Provincial Association of Doctor- Surgeons and Dentists in Florence, Italy: Licenced on 30 November 1983, Registered on 23 January 1984, Licence number 7745 General Medical Council (UK) Registration: 18 June 2012, Registration n°7125393 Schweizerische Eidgenossenschaft (Swiss Confederation) Registration: 7 November 2012, Registration n° GNL7601000979667 Medical Board of California, USA: November 13, 2013 - November, 13 2014, Registration n°F5799, NPI n° 19322939038, DEA Registration number: FP4286628 (2113 Permit) Medical Board of California, USA: March 29, 2018 - December 12, 2019, Registration n°SFP000035, NPI n° 19322939038, DEA Registration number: FP4286628 (2168 Permit)

2. PROFESSIONAL APPOINTMENTS Present Employment Since 1989 Founder, Owner, CEO, Administrator, Strategic and Scientific Director, Istituto di Neuroscienze, Via A. Lamarmora 24, Firenze, Italy, A private institution for research, diagnosis, rTMS and tDCS therapy in Psychiatry, Neurology and Clinical Psychology. Accredited by the University of Florence for Post-Graduate Internship. Since 2004 Founder, Director and Administrator, Clinical Neurosciences ONLUS, Via Dè Fossi 12, Firenze, Italy, A non-profit organization that organizes scientific CME courses in collaboration with the University of Florence (Italy) Academic Appointments 2001 – 2020 Tenured Professor of Psychiatry University of Florence, School of Medicine, Florence, Italy 2000 – 2010 Scientific Secretary and Coordinator, Tuscany School of Psychiatry (Three Tuscan Universities' Consortium: University of Florence, Pisa and Siena) 2004 Board Member and Coordinator, International Affairs Office of the University of Florence Since 2004 Member of Board of Directors, International Master in Affective Neuroscience, University of Maastricht, The Netherlands and University of Florence, Italy 2004 – 2005 Visiting Associate Professor in Overseas Studies, Stanford Program in Florence, School of Humanities and Sciences, Stanford University 2004 – 2005 Professor in Emergency Psychiatry, Emergency Medicine Post Doctorate Master course, Harvard School of Medicine, Massachusetts, U.S. and University of Florence, Florence, Italy 2006 – 2007 Director and Organizer, Medical School Course of Psychiatry in English, University of Florence, Italy 2007 – 2008 Director, Strategic Center of Excellence of Psychiatry, Icahn School of Medicine at Mount Sinai New York, USA Since 2008 Member of Board of Directors, Dottorato Toscano di Neuroscienze, University of Florence, School of Medicine, Florence, Italy 2008 - 2010 Director of Master in Mindfulness (“Meditation and Mindfulness: Neurosciences and Clinical applications in Health Care”) University of Florence Since 2010 Director of the Graduate Course on Health Education, University of Florence, School of Medicine, Florence, Italy

3. Since 2010 Chair of Education and Director of the Residency Program of Psychiatry, University of Florence, School of Medicine, Florence, Italy Since 2012 Italian National Scientific Qualification as a full professor 2013 - 2014 Professor of Psychiatry and Behavioral Sciences, Early Diagnosis and Preventive Treatment Clinic, Psychosomatic Unit, Responsible for the Neuromodulation Program, UC Davis, CA, USA Since 2013 Visiting Professor, Albert Einstein College of Medicine, Montefiore Medical Center New York, USA 2013 Qualified as a Full Professor, University of Florence Since 2016 Visiting Professor, Imperial College, London, UK 2017 – 2019 Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology (Adult), Stanford University, Stanford, CA, USA Since 2018 Faculty, Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale Since 2019 Faculty, The European Network for Problematic Usage of the Internet, Training School at Clare College, Cambridge University Since 2019 Faculty, International Psychopharmacology Course, Harvard University and Massachusetts General Hospital Psychiatry Academy Since 2022 Honarary Professor, Instituto Universitario de Neurociencias, Universidad de La Laguna, San Cristóbal de La Laguna, Spagna Clinical Activities 1984 –1988 Chief Residency in Psychiatry 1988 –1990 Residency in Neurology 1990 –1993 Residency in Clinical Neurophysiology Since 1989 Clinical Director, Istituto di Neuroscienze, Italy 2000 – 2020 Dirigente Medico 1st level (Medical Director), Psychiatric Clinic, Azienda Ospedaliero Universitaria Careggi (University of Florence Hospital), Department of Neuropharba 2000 – 2020 Director of the OCD Spectrum Disorders programme, Psychiatric Clinic, Azienda Ospedaliero Universitaria Careggi, University of Florence Hospital, Department of Neuropharba 2009 - 2014 Director of Psychosomatic and Liaison psychiatry, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

4. 2013 - 2014 Clinical Practice, Sacramento EDAPT and EDAP programs (Early Diagnosis and Preventing Treatment of Psychosis Illness), Liaison Psychiatry Consultant, UC Davis Medical Hospital, CA, USA 2018 - 2019 Professor of Psychiatry and Behavioural Sciences, Stanford University, CA, USA Professional Memberships and Services Since 1994 International Advisory Board member, American Psychiatric Association (APA) for DSM V and DSM 5.0 TR Since 1999 Member of the Steering Committee, International OCD Consortium Since 2000 Member of Board of Directors, International Master in Affective Neuroscience, Universities of Maastricht and Florence Since 2004 Board member, International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), UK Since 2004 Scientific Advisory Panel Member for Anxiety and Anxiolytics session, European College of Neuropsychopharmacology (ECNP) Since 2005 Member of International Advisory Board, American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer) 2005 - 2007 Member of the OCD spectrum workgroup Impulse Control Disorders Taskforce and International Advisory Board, American Psychiatric Association (APA) for DSM 5.0 (Chair D.J. Kupfer) Since 2009 Member of the Advisory Council, icare4autism (International Center for Autism Research and Education), New York, USA 2011 –2014 Member of the European College of Neuropsychopharmacology Educational Committee Since 2011 Member of the ECNP Obsessive Compulsive and Related Disorders Network Since 2013 Fellow, European College of Neuropsychopharmacology Since 2013 Member of the New York Psychiatric Society, NY, USA 2013 – 2017 Member of the Board of Directors, Clinical TMS Society, Greenwich, CT, USA Since 2014 World Health Organization expert in Anxiety Since 2014 International Fellow, American Psychiatric Association (APA) Since 2015 Member of the Board, (anxiety section) World Psychiatric Association

5. 2016 - 2019 Executive Committee Member, European College of Neuropsychopharmacology Since 2017 Ambassador, European College of Neuropsychopharmacology Since 2017 Member of the PANDAS Physicians Network Since 2018 Board member, European Research Area Networks NEURON (ERA-NET NEURON) Since 2019 Chair, Neuromodulation Network, European College of Neuropsychopharmacology Since 2020 International Expert, German Association of Scientific Medical As sociations on behalf of the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJPP) for development of the interdisciplinary evidence- and consensus-based S3-Guideline for the diagnosis and treatment of obsessive-compulsive disorder in childhood and adolescence (interdisziplinäre evidenz- und konsensbasierte S3- Leitlinie für Diagnostik und Therapie von Zwangsstörungen im Kindes- und Jugendalter) Since 2020 Member of the International Neuroethics Society Since 2020 Board member, The European Commission consensus initiative on depression and its treatment (EU PEARL) Since 2021 Member, WHO - World Health Organization funded COVID-19 Clinical Re- search Coalition’s Ethics Working Group, the Good Clinical Practice Al- liance – Europe (GCPA) Service as a member of Grant Review Committee 2011 Member of Research Funding Evaluation Committee, UK General Medical Research Council Since 2011 Member of the Board of Research Funding Evaluation Committee SAMENTA, Agence Nationale dela Recherche, Paris, France 2013 Member of the Expert Review Board, The ERA-NET scheme of the European Commission 'Network of European Funding for Neuroscience Research' (NEURON) for its funding initiative "European Research Projects on Mental Disorders" Since 2018 Member of the Spark Evaluation Committee, the Swiss National Science Foundation (SNSF) 2020 Specialist Evaluating Committee Member, National Research Foundation (NRF), South Africa 2020 Board of Reviewers, Catalan biomedical research funding programme "La Marató de TV3", Agency for Health Quality and Assessment of Catalonia, Spain

6. Professional Honors and Awards October 2004 ECNP poster-travel award February 2005 Società Italiana di Psicopatologia (SOPSI) poster research award May 2007 CNS Spectrum 2007 Breakthrough Paper Award TEACHING Master Training Class in Neuromodulation, European College of Neuropsychopharmacology (ECNP) Since 2020 Organizer and speaker for ECNP Network, Thematic Working Group University of Florence, Italy 1993 - 2019 Psychopathology Course (Course Director and Lecturer) 1993 – 2019 Psychopathology in the Residency Programme (Course Director and Lecturer) 2000 – 2019 Undergraduate Psychiatry Course (Course Director and Lecturer) 2001 – 2019 Medical Thesis Advisor 2006 - 2007 English language Medical School Course of Psychiatry (Director) 2007 – 2019 Suicide Prevention Course for Medical students, Nurse and Social Workers (Director) 2010 – 2019 Psychopharmacology Course (Course Director and Lecturer) 2012 – 2012 Master's Program in Mindfulness (Director) 2016 - 2017 Neurocircuitry Research Domain Criteria and Precision Psychiatry Course (Course Director and Lecturer) 2010 - Present Post-Graduate Psychiatry Course (Course Director and Lecturer) Weekend Educative Course in Psychiatry, India 2017 – 2018 Elite faculty for enforcement program of neuropsychiatry in India University of Maastricht and University of Florence, 1995 - Present International Master Degree in Affective Neuroscience (joint program) - course design, material development, lectures, and thesis advising

7. Continuing Medical Education (CME) European Accreditation Council for CME 2009 - 2013 Managing Anxiety in Practice CME Course design, course material development (Slides, Booklet and CD-ROM) and lectures. Total of 6 courses held in Berlin (Germany), London (UK), Athens (Greece), Rome (Italy), Munich (Germany) and Paris (France) Florence Summer Course – Organizer, Scientific Director, Chair and Speaker 2004 7 - 14 Aug. Anxiety and Impulsivity 2005 30 July - 1 Aug. Neuroscience of Affective Disorder Spectrum 2006 14 -15 Sept. Psychiatric Disorder and Day Hospital 2007 31 Ago. - 3 Sept. Anxiety Disorders and Psychosis 2008 4 - 6 Sept. Aspect of Contemporary Psychiatric Disorders 2009 5 - 7 Sept. A Lesson on Great American Studies on Efficiency and Personalized Therapies in Psychiatry 2010 3 - 5 Sept. Aspect of Contemporary Psychiatry 2011 9 - 11 Sept. Toward and Individualized Therapy – Evolution of Psychiatry, from Disorder to “Research Domain” 2012 19 - 21 Oct. Quality in Clinical Psychiatry 2013 11 - 12 Oct. Clinical Staging and Pathophysiology of Brain Desease 2014 23 - 24 Oct. Total Resources: Look after Brain Disorders and Take Care of Mental Suffering Coordinator, Interuniversity cooperation agreements Since 2004 Board member of the International Affairs Office of the University of Florence, On-going International educational collaborative programmes between Univ. of Florence and: Columbia University (USA) in 2010 University of Balamand (Lebanon) in 2009 Mount Sinai School of Medicine (USA) in 2004 Stanford University (USA) in 2004 SCHOLARSHIP Peer-Reviewed Original Research Publications (extracts) 1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, Pallanti S, Vita A. Recent life events and affective disorder revisited. British Journal of Psychiatry. 1986 Mar;148:288-95.

8. 2. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. American Journal of Psychiatry. 1986 Jul;143(7):888- 91. 3. Faravelli C, Pallanti S. Clomipramine by different routes of administration: short- and long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull. 1987;23(3):459-63. 4. Faravelli C, Pallanti S, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic attacks with and without agoraphobia: a comparison. Psychopathology. 1988;21(1):51-6. 5. Faravelli C, Pallanti S, Strik WK. [Stress load and schizophrenic disorder]. Nervenarzt. 1988 Apr;59(4):237-9. German. 6. Faravelli C, Pallanti S. Recent life events and panic disorder. American Journal of Psychiatry. 1989 May;146(5):622-6. 7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G, Faravelli C, Pallanti S, Bressa G. Familial analysis of panic disorder and agoraphobia. Journal of Affective Disorders, 1989, vol.17, p.1-8. ISSN: 0165-0327. 8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, Pallanti S. Epidemiology of mood disorders: a community survey in Florence. Journal of Affective Disorders. 1990 Oct;20(2):135-41. 9. Faravelli C, Panichi C, Pallanti S, Paterniti S, Grecu LM, Rivelli S. Perception of early parenting in panic and agoraphobia. Acta Psychiatrica Scandinavica. 1991 Jul;84(1):6-8. 10. Faravelli C, Pallanti S, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder. American Journal of Psychiatry. 1992 Jun;149(6):827-8. 11. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biological Psychiatry. 1992 Jul 1;32(1):91-5. 12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A, Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease. Journal of the Neurological Science. 1992 Oct;112(1-2):81-9. Volume 112, Issues 1– 2, 1992, 13. Pages 81-89. ISSN 0022-510X. https://doi.org/10.1016/0022-510X(92)90136-9. a. (https://www.sciencedirect.com/science/article/pii/0022510X92901369) 14. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli, S.Pallanti, J.Lepine, P.Pariente, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori, W.Maier (1992). The changing rate of depression. JAMA, vol. 268, p. 3098-3105, ISSN: 0098-7484. 15. Pallanti S., Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica. [Dementia in a psycho(patho)logical perspective] Jornal Brasiliero de Psiquiatria [Brazilian Journal of Psychiatry] 41 (9), 447-50. Ott. 1992.

9. 16. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Assessment of onset of panic disorder in relatrion to onset of agoraphobia-replay. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01. 17. Pallanti, S. et al. Depth perception in schizophrenia. Biological Psychiatry, Volume 35, Issue 9, 637 – 638 Published in issue: May 01, 1994 18. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, Pallanti S, Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and Russian families with schizophrenia. Neuroscience Letters 1994 Jan 3;165(1-2):45- 7. 19. Grassi E, Mortilla M, Amaducci L, Pallanti S, Pazzagli A, Galassi F, Guarnieri BM, Petruzzi C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No evidence of linkage between schizophrenia and D2 dopamine receptor gene locus in Italian pedigrees. Neuroscience Letters 1996 Mar 15;206(2-3):196-8. 20. Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L, Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive- compulsive disorder. Biological Psychiatry. 1996 Dec 1;40(11):1164-72. 21. Pallanti S, Koran LM. Two case report. CNS Spectrums 1996, vol.1, p.54-57, ISSN: 1092-8529. 22. Bersani G., Saito A. Pallanti S. Sasso E., Tosca P. Clinical variables and response to citalopram in Major Depression: an open multicentric study. Rivista di Psichiatria 32, 260-267, 1997. 23. Pallanti S. Personality Disorders: Myths and Neuroscience. CNS Spectrums 2, 53-63, 1997. 24. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry. 1997 Mar;154(3):396-401. 25. Pallanti S, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic patients: a prospective study of stressful life events, P300 measures, and coping. American Journal of Psychiatry. 1997 Jun;154(6):792-8. 26. Ramacciotti A, Pallanti S, Pazzagli A. A setting including psychotherapy and psychopharmacological treatment in a case of anorexia nervosa with obsessive compulsive disorder comorbidity. Eating and Weight Disorders. 1997 Dec;2(4):222- 8. 27. Inzitari D, Pantoni L, Lamassa M, Pallanti S, Pracucci G, Marini P. Emotional arousal and phobia in transient global amnesia. Archives of Neurology. 1997 Jul;54(7):866-73. 28. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. Eating and Weight Disorders. 1997 Dec;2(4):216-21.

10. 29. Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement abnormalities in anorexia nervosa. Psychiatry Research. 1998 Mar 20;78(1-2):59-70. 30. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1998 May;8(2):121-6. 31. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biological Psychiatry. 1998 Aug 1;44(3):220-7. 32. Pallanti, S., Quercioli, L. Cognitive subjective disturbances of schizophrenia: Effect of atypical neuroleptics. European Neuropsychopharmacology, 1999 33. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999- 01-01. 34. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796. 10327919. 35. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Research. 1999 Jun 30;86(3):239-49. 36. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB. Awareness of illness and subjective experience of cognitive complaints in patients with bipolar I and bipolar II disorder. American Journal of Psychiatry. 1999 Jul;156(7):1094-6. 37. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry. 1999 Apr;14(2):101-6. 38. Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in young schizophrenic patients. Comprehensive Psychiatry. 1999 Sep- Oct;40(5):363-71. 39. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, Pallanti S, Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. British Journal of Psychiatry 1999.467-71. 40. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. Journal of Clinical Psychiatry. 1999 Dec;60(12):819-23. 41. Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event- related potentials in obsessive-compulsive disorder without panic disorder or depression comorbidity. Journal of Psychiatric Research. 2000 Jan-Feb;34(1):75-82. 42. Pallanti S, Quercioli L. Shame and psychopathology. CNS Spectrums. 2000 Aug;5(8):28-43.

11. 43. Pallanti S, Quercioli L, Pazzagli A. Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine. CNS Spectrums. 2000 Sep;5(9):29-43. 44. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Comprehensive Psychiatry. 2000 Nov- Dec;41(6):446-9. 45. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. European Neuropsychopharmacology. 2001 Apr;11(2):169-72. 46. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazzini D., Rasmussen S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry 63, 20-29, 12-2001. 47. Pallanti S., Quercioli L. Alternative route of administration and titration of SRIs in anxious resistant patients:Two day-hospital experiences. European Neuropsychopharmacology 11, S312, 2001-12-31. 48. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, Pallanti S. Attachment processes in eating disorders. Eat Weight Disord. 2001 Sep;6(3):166-70. 49. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB. Kleptomania: clinical features and comorbidity in an Italian sample. Comprehensive Psychiatry. 2002 Jan-Feb;43(1):7-12. 50. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry. 2002;63 Suppl 6:20-9. 51. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. International Journal of Neuropsychopharmacology. 2002 Jun;5(2):181-91. 52. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. Journal of Clinical Psychiatry. 2002 Jul;63(7):559-64. 53. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry. 2002 Sep;63(9):796-801. 54. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. Journal of Clinical Psychiatry. 2002 Nov;63(11):1034-9.

12. 55. Buchsbaum M.S., Hollander E., Pallanti S., Baldini-Rossi N. Brikman A.M., Platholi J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in SRI-refractory patients. Biological Psychiatry 51 (8), 47S-47S, 2002- 04-14. 56. Pallanti S., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse- Control Disorders Not Otherwise Specified (NOS). Biological Psychiatry 2003, 1315- 1329. 57. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling. Current Psychiatry Reports. 2003 May;5(1):9-15. 58. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo- controlled study. International Journal of Neuropsychopharmacology. 2003 Dec;6(4):397-401. 59. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. American Journal of Psychiatry. 2004 Jan;161(1):53-8. 60. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry. 2004 Oct;65(10):1394-9. 61. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2004;65 Suppl 14:6-10. 62. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained- release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? American Journal of Psychiatry. 2005 Jan;162(1):137-45. 63. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. Journal of Gambling Studies. 2005 Spring;21(1):99-110. 64. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biological Psychiatry. 2005 Apr 1;57(7):733-42. 65. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatologic Clinics. 2005 Oct;23(4):601-8. 66. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis: from empiric data to the evolutionary hypothesis. Dermatologic Clinics. 2005 Oct;23(4):695-701.

13. 67. Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS. Imaging monetary reward in pathological gamblers. World Journal of Biological Psychiatry. 2005;6(2):113-20. 68. Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V. Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism. Clinical Practice & Epidemiology in Mental Health. 2005 Nov 15; 1:24. 69. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability, and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). Journal of Gambling Studies. 2005 Winter;21(4):431-43. 70. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the EQUIP group). Reliability and validity of the Italian version of the Quality of Life, Enjoyment and Satisfaction Questionnaire. Quality of Life Research. 2005 Dec;14(10):2323-8. 71. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2006 May;30(3):400-12. 72. Pallanti, S. (2006). From Impulse-Control Disorders Toward Behavioral Addictions. CNS Spectrums. 11. 921-922. 10.1017/S1092852900015108. 73. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology. 2006;53(3):157-68. 74. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectrums. 2006 Dec;11(12):956-64. 75. Pallanti S, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high-school population: prevalence and related disability. CNS Spectrums. 2006;11(12):966-74. 76. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clinical Practice & Epidemiology in Mental Health. 2006;13; 2:35. 77. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectrums. 2007 Feb;12(2 Suppl 3):5-13. 78. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. International Clinical Psychopharmacology 2007;22(6):313-22. 79. Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice. 2007; 11(3): 233-238.

14. 80. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American Journal of Psychiatry. 2008 Feb;165(2):169-70. 81. Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive compulsive disorder comorbidity in DBA. Clinical Practice & Epidemiology in Mental Health. 2008 Mar 10; 4:6. 82. La Malfa G, Lassi S, Bertelli M, Pallanti S, Albertini G. Detecting attention- deficit/hyperactivity disorder (ADHD) in adults with intellectual disability the use of Conners' Adult ADHD Rating Scales (CAARS). Research in Developmental Disabilities. 2008 Mar-Apr;29(2):158-64. 83. Pallanti S. Brain plasticity and brain stimulation in neuropsychiatry: toward individualized medicine. CNS Spectrums. 2008 Apr;13(4):287-92. 84. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral, and cingulated metabolism. Neuropsychobiology. 2008;58(1):37-47. 85. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific "metaphor". CNS Spectrums. 2008 Sep;13(9 Suppl 14):6-15. 86. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in the treatment of obsessive-compulsive disorder. Biological Psychiatry 63 (7), 170S-170S, 2008-04-01. 87. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. International Clinical Psychopharmacology 2009 Jul;24(4):163-73. 88. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence, and correlates of mental disorders in a school-survey sample. Clinical Practice & Epidemiology in Mental Health 2009 Nov 24; 5:1-8. 89. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA. Cognitive event-related potentials differentiate schizophrenia with obsessive- compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. Psychiatry Research. 2009 Nov 30;170(1):52-60. 90. Potenza MN, Koran LM, Pallanti S. The relationship between impulse-control disorders and obsessive-compulsive disorder: a current understanding and future research directions. Psychiatry Research. 2009 Nov 30;170(1):22-31. 91. Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on comorbidities and dissociative symptoms. Comprehensive Psychiatry. 2009 Nov- Dec;50(6):510-6. 92. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009 Dec;23(12):1047-55.

15. 93. Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS Spectrums. 2009 Dec;14(12):668-70. 94. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? Neuroscience. 2010;5;167(2):323-8. 95. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S. Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation in Parkinson's disease. Parkinsonism and Related Disorder. 2010 Jul;16(6):376-80. 96. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms, and Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with Resistant Depression. Case Reports in Medicine. 2010; 2010:836214. 97. Schlaepfer TE, Lisanby SH, Pallanti S. Separating hope from hype: some ethical implications of the development of deep brain stimulation in psychiatric research and treatment. CNS Spectrums. 2010 May;15(5):285-7. 98. Pallanti S., Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive Transcranical Magnetic Stimulation and Depression: Separating Hope From Hype. CNS Spectrums 15 (9), 554-557, 2010. 99. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS. Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology. 2010;62(2):132-8. 100. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7. 101. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World Journal of Biological Psychiatry. 2010 Jun;11(4):656-66. 102. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E. Noradrenergic function in pathological gambling: blunted growth hormone response to clonidine. Journal of Psychopharmacology. 2010 Jun;24(6):847-53. 103. Bernardi S, Pallanti S. Successful duloxetine treatment of a binge eating disorder: a case report. Journal of Psychopharmacology. 2010 Aug;24(8):1269-72. 104. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A, Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation. Journal of Neurology. 2010 Aug;257(8):1362-8. 105. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-BruguÃ M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P,

16. Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;3; 10:67. 106. Pallanti S. Augmentation strategies in resistant obsessive-compulsive disorders (OCD), International Journal of Psychiatry in Clinical Practice 14, 15-16, 2010-11-01. 107. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. Journal of Psychopharmacology. 2010 Dec;24(12):1802-9. 108. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6. 109. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment- resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2011 May;72(5):716-21. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript 110. Di Rollo A, Pallanti S. Phantom limb pain: low frequency repetitive transcranial magnetic stimulation in unaffected hemisphere. Case Reports in Medicine. 2011; 2011:130751. 111. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychological Medicine. 2011 Aug 16:1-13. *Provided study ideas and concept, participated in the drafting and revision of the manuscript, and provided mentorship to first author 112. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive- compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry. 2011; 2:70. 113. Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D, Pallanti S, Pantoni L. Major depression and bipolar disorders in CADASIL: a study using the DSM-IV semi-structured interview. Acta Neurologica Scandinavica. 2011 Dec;124(6):390-5. *Participated extensively in conception and trial design, acquisition, analysis and interpretation of data, participated in drafting, reviewing and critical revision of the manuscript. 114. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World Journal of Biological Psychiatry. 2012; 13(7):510-6. 115. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In Obsessive-Compulsive Disorder, J. Zohar (Ed.) https://doi.org/10.1002/9781119941125.ch5 116. Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology. 2012;

17. 26(7):861-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript 117. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G, Quercioli L. rTMS age-dependent response in treatment resistant depressed subjects: a mini- review, CNS Spectrums (2012), 17, 24-30. 118. S. Pallanti, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant Depression: Cognitive Improvement is Independent from Clinical Response, Neuropsychobiology 2012 Jun; 65(4):227-35. 119. Moretti S., Arunachalam M., Colucci R., Pallanti S., Kline JA., Berti S., Lotti F., Lotti T. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. Journal of the European Academy of Dermatology and Venereology 2012; 26 (7), 861-867. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript. 120. Pallanti S, Salerno L. Pharmacological treatment and management of attention deficit hyperactivity disorder (ADHD) in adults. Minerva Psichiatrica 2013 Dec; 54(4);297-315. ISSN: 1827-1731 121. Pallanti. S. The Placebo Effect in Clinical Practice. American Journal of Psychiatry 2013 170:8, 931-932 122. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clinical and Experimental Rheumatology. 2012;31(2):318-9. *Participated extensively in conception, drafting, reviewing and critical revision of the manuscript 123. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment Resistance. In Obsessive-Compulsive Disorder, J. Zohar (Ed.) https://doi.org/10.1002/9781119941125.ch5 124. Baldwin DS, Pallanti S, Zwanzger P. Developing a European Research Network to Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral Reviews. 2013; 37(10 Pt 1):2312-7. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript 125. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S, Inzitari D, Pallanti S, Pantoni L., Facial Affect Recognition in CADASIL Patients., Archives of Clinical Neuropsychology 2013;28(1):65-71. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript 126. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128. *Participated extensively in conception and trial design, participated in drafting, reviewing and critical revision of the manuscript

18. 127. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia. Current Psychiatry Reports. 2013;15(5):354. 128. Dell’Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder, a report from the International College of Obsessive- Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology. 2013 Aug; 23(8):865 71. *Participated extensively in conception and trial design, acquisition and analysis of data, participated in drafting, reviewing and critical revision of the manuscript 129. Pallanti S, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral Addictions: From Behavioral Dimensions to the Research Domain Criteria Based Target. Current Psychopharmacology, 2013; 2(3):183-189. 130. Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case Reports in Psychiatry. 2013; 2013:930304. 131. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums. 2014; 19(1):50-61. 132. Carelli R, Pallanti S. Streptococcal infections of skin and PANDAS. Dermatologic Therapy. 2014 Jan; 27(1):28-30. 133. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypocondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS Spectrums. 2014; 9(4):340-6. 134. Van Ameringen S, Simpson W, Patterson B, Dell’Osso B, Finebg n, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar, J. Pharmachological treatment strategies in obsessive-compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology 2014; 28(6):596-602. *Participated extensively in conception and trial design, authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript 135. Di Rubbo R., Sogaro E., Pallanti, S. Communicative evolutive psychotherapy adapted for the psychodynamic group setting in the treatment of pathological interpersonal dynamics of identity. Dynamische Psychiatrie. 2013; 46(3): 204-233. 136. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive disorders. Expert opin Emerg Drugs, 2014 Mar; 19(1):66-77. 137. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: An exploratory study. J Affect Disord. 2014; 157:66-71. 138. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to

19. serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014; 24(3):375-380. 139. Pallanti S, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to neurocircuits: what we can learn from DBS? The case of obsessive-compulsive disorder. J. Psychopathol. 2014; 20:27-32. 140. Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano MAlattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment for major depression. Pharmacopsychiatry.2014 May;47(3), 105-10. *Member: Pallanti S. *Acquisition of data 141. Pallanti S, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary data. International Journal of Psychiatry in Clinical Practice. 2014; 18(4):255-60. 142. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven_Wetzler A, Altamura AC Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, Pallanti S, Stein DJ, Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorder (ICOCS). Comprehensive Psychiatry. 2014;55(7):1513-9. *Participated extensively in conception and trial design, drafting, reviewing and critical revision of the manuscript 143. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder comorbidity. Expert Opin Pharmacother. 2014;15(17):2543-52. 144. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M; Italian Network for Research on Psychoses. The Specific Level of Functioning Scale: construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research. 2014; 159(1):144-50. *Member: Pallanti S. *Acquisition of data 145. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014; 13(3):275-87. *Member: Pallanti S. *Acquisition of data 146. Cantisani, A., Grassi, G., Pagano, L., Comanducci, A., Lanzo, G., Amantini, a., Grippo, a., Salerno, L., Pallanti, S. Neurophysiological alterations in adults with attention deficit/hyperactivity disorder: an event-related potential study. European Neuropsychopharmacology 24:S714-S715 · October 2014. DOI: 10.1016/S0924-977X(14)71151-4 147. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive- behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation. 2015; 8(1):160- 1.

20. 148. Pallanti S, Salerno L. Raising attention to attention deficit hyperactivity disorder in schizophrenia. World Journal of Psychiatry. 2015;5(1):47-55. 149. Grassi, G., Pallanti, S. Citalopram Pulse-Loading for Treatment-Resistant Obsessive-Compulsive Disorder: Preliminary Data from an Open-Label Trial. European Neuropsychopharmacology, Volume 26, Issue 5, 2016, Pages 898-899, ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2015.06.034. 150. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from International College of Obsessive Compulsive Spectrum Disorder (ICOCS). CNS Spectrums. 2015; 20(5):469-73. *Participated extensively in conception, participated in drafting, reviewing and critical revision of the manuscript 151. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorder: Implications for interventions and therapeutics. World Journal of Biological Psychiatry. 2015; 15:1-13. *Authorship of sections of the manuscript, participated in drafting, reviewing and critical revision of the manuscript 152. Pallanti, S., Grassi G, Marras A, Hollander E. Can we modulate obsessive- compulsive networks with neuromodulation? J Psychopatol, 21:262-265. 153. Pallanti, S., Marras A, Grassi G. Outcomes with neuromodulation in obsessive- compulsive disorder. Psych Annals, 45(6):316-320. 154. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation Treatment for Motor Symptoms in Parkinson's Disease: A Review of Two Decades of Studies. Journal of Alzheimer’s Disease & Parkinsonism. 05. 10.4172/2161-0460.1000191. 155. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation in Alzheimer’s Disease: A Review of Investigational and Therapeutic Findings. J Alzheimers Dis Parkinsonism 5:187. doi:10.4172/2161-0460.1000187 156. Grassi, G., Molesti E., Lori S., Pallanti S., Cheli E., Marras A. "OR-38: neuromodulation of decision-making networks with alfaEEG-guided repetitive transcranic magnetic stimulation: preliminary results from a pilot study." Journal of Behavioral Addictions, vol. 5, no. S1, 2016, p. 17+. 157. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, Van Balkom A J, New treatment models for compulsive disorders. European Neuropsychopharmacology 2016; 26(5):877-84. *Participated extensively in conception, acquisition of data, authorship of sections of the manuscript 158. Grassi G, Pallanti S, Righi L, Figee M, Mantione M, Denys D, Piccagliani D, Rossi A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive disorder. Journal of Behavioral Addiction 2015;4(4):263-72. *Provided study ideas, participated in the drafting, reviewing and revision of the manuscript, and provided mentorship to first author

21. 159. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review, and pilot open-label trial. Journal of Psychopharmacology. 2016; 30(6):568-78. 160. Menchon JM, Van Ameringen M, Dell’Osso B, Denys D, Figee M, Grant JE, holander E, Marazziti D, Nicolini H, Pallanti S, Ruck R, stein DJ, Andersson E, bipeta R, Cath DC, drummond L, Feusner J, Geller DA, Hranov , lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O’Kearney R, pasquini M, Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP, Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive disorders centres. International Journal of Psychiatry in Clinical Practice. 2016;20(3):204-8. *Participated extensively in conception and trial design, acquisition of data and in drafting 161. Marras A, Fineberg N, Pallanti S. Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. CNS Spectrums. 2016;21(4):324-33. 162. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, bourin M, Chamberlain SR, Cinosi E, Davies S, Domscchke K, Fineberg N, Grunblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P. Biological markers for anxiety disordrs, OCD and PTSD: a consensus statement. Part II: Neurochemistry, neurophisiology and neurocognition. World Journal of Biological Psychiatry. 2016; 15:1-53. *Participated extensively in conception and trial design, acquisition,authorship of sections of the manuscript 163. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. J Psychiatr Res. 2016 Dec;83:240-248. doi: 10.1016/j.jpsychires.2016.09.012. Epub 2016 Sep 14. PMID: 27665536. 164. Dell’Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hrano L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice. 2016; 19:1-8. *Participated extensively in conception and trial design, acquisition of data and in drafting 165. Pallanti S. ICD and DSM: Neuroplasticity and Staging are still missing. CNS Spectrums. 2016 Aug:21(4):276-8. 166. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A, Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A, Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; Italian Network for Research on Psychoses. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res 2016; 175(1-3):154-60. *Member: Pallanti S. *Participated extensively in conception and

22. trial design, acquisition, analysis of data, reviewing and critical revision of the manuscript 167. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C, Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P, Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M; Italian Network for Research on Psychoses. Social cognition in people with schizophrenia: a cluster-analytic approach. Psychol Med 2016 Oct;46(13):2717-2729 *Member: Pallanti S. *Participated extensively in conception and trial design, acquisition, participated in drafting, reviewing and critical revision of the manuscript 168. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE, Hollander E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8. *Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript 169. Giordano F, Cavallo M, Spacca B, Pallanti S, Tomaiuolo F, Pieraccini F, Fagiolini A, Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive Behaviour. Stereotact Funct Neurosurg. 2016 Nov 1;94(6):371-378. *Participated extensively in conception and trial design, acquisition of data and in drafting 170. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract. 2016 Nov;20(4):210-7. *Participated extensively in conception and trial design, acquisition of data and in drafting, reviewing and critical revision of the manuscript 171. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C, Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation. J Psychiatr Res. 2016 Dec; 83:240-248. 172. Chiariello F, Spitoni S, Hollander E, Pallanti S. An expert opinion on PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in Clinical Practice 2017; 1-8 Published online: 13 Feb 2017 173. Salerno L, Makris N, Pallanti S. Raadult ADHD: a key feature. Journal of Psychopathology 2016; 22:135-140. 174. Pallanti S. Biological Markers for Anxiety Disorders, OCD and PTSD – A Consensus Statement – Part II: Neurochemistry, Neurophysiology and Neurocognition. The World Journal of Biological Psychiatry World J Biol Psychiatry. 2017 Apr;18(3):162- 214.

23. 175. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2017 Mar 16:1-8. 176. Dell’Osso B, Marazziti D, Albert U, Pallanti S, Gambini G, Tundo A, Zanaboni C, Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. Int J Psychiatry Clin Pract. 2017 Jun;21(2):156-159. 177. Salerno L, Burian I, Pallanti S. A new generation rating scale for depression: Reliability and Validity of the Italian version of Symptoms of Depression Questionnaire (SDQ), an RDoC-oriented depression comprehensive assessment. Journal of Psychopathology, 2017 23:1-12. 178. Grassi, G., Pacini, S., Cecchelli C., Pallanti, S. Enhancing inhibition processes during cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive transcranial magnetic stimulation. S1009. European Neuropsychopharmacology, 2017 179. Grassi, G., & Pallanti, S. (2017). Common Neural Networks Between OCD and Behavioural Addictions: Is LCD a Behavioural Addiction? European Psychiatry, 41(S1), S21-S22. Doi:10.1016/j.eurpsy.2017.01.120 180. Lusicic A, Schruers KR, Pallanti S, Castle DJ. Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2018 Jun 29;14:1721-1736. doi: 10.2147/NDT.S121140. PMID: 29988759; PMCID: PMC6029675. 181. Micheli L., Spitoni S, Di Cesare Mannelli L., Billa A.R., Pallanti S. Bacopa Monnieri as augmentation therapy in the treatment of anhedonia,preclinical and clinical evaluation. 01 April 2020 http10.1002/ptr.6684 182. Grassi G, Figee M, Ooms P, Righi L, Nakamae T, Pallanti S, Schuurman R, Denys D. Impulsivity and decision-making in obsessive-compulsive disorder after effective deep brain stimulation or treatment as usual. CNS Spectr. 2018 Jun 4:1-7 183. Burchi E, Pallanti S. Antibiotics for PANDAS? Limited Evidence: Review and Putative Mechanisms of Action. Prim Care Companion CNS Disord. 2018 May 3;20(3). 184. Burchi E, Pallanti S. Diagnostic Issues in Early-Onset Obsessive-Compulsive Disorder and Their Treatment Implications.Curr Neuropharmacol. 2018 Apr 26. 185. Fineberg NA, Chamberlain SR, Menchon J, Demetrovics D, Grünblatt E, Pallanti S, Carmi L, Billieux J, King D, Dellosso B, Van Ameringen M, Hall N, Potenza M, Hollander E, Zohar J and the COST Action EU-PUI Network. Manifesto for a

24. European Research Network into Problematic Usage of the Internet. 2018, in submission. 186. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR. Version 2. Manifesto for a European research network into Problematic Usage of the Internet. Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. Doi: 10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID: 30509450 187. Burchi E, Hollander E, Pallanti S. From Treatment Response to Recovery: A Realistic Goal in OCD. Int J Neuropsychopharmacol. 2018 Nov 1;21 (11):1007-1013. doi: 10.1093/ijnp/pyy079. PMID:30184141 188. Grassi G, Pallanti S. Expert Opinion Pharmacother. 2018 Oct;19(14):1541-1550. Doi:10.1080/14656566.2018.1528230. Epub 2018 Oct 15. PMID:3021070 189. Sali L, Ventura L, Grazzini G, Borgheresi A, Delsanto S, Falchini M, Mallardi B, Mantellini P, Milani S, Pallanti S, Zappa M, Mascalchi M. Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial. Eur Radiol. 2018 Nov 6. doi: 10.1007/s00330-018-5808-1. [Epub ahead of print] PMID:30402705 190. Scarpino, M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu Cesarina, Bastianelli M, Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A. Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the Magne Tox study): A study protocol for a randomized placebo-controlled pilot trial. Neurophysiologie Clinique, 10 2018 191. Grassi, G., Pallanti, S. Current and up-and-coming pharmacotherapy for obsessive- compulsive disorder in adults, Expert Opinion on Pharmacotherapy, 19:14, 1541- 1550, DOI: 10.1080/14656566.2018.1528230 2018 192. J.J.S. Kooija, D. Bijlengaa, L. Salerno, R. Jaeschkea, I. Bittera, J. Balázsa, J. Thomea, G. Doma, S. Kaspera, C. Nunes Filipea, S. Stesa, P. Mohra, S. Leppämäkia, M. Casas Bruguéa, J. Bobesa, J.M. Mccarthya, V. Richartea, A. Kjems Philipsena, A. Pehlivanidis,b , A. Niemela, B. Styr, B. Semerci, B. Bolea-Alamanac, D. Edvinsson, D. Baeyens, D. Wynchank, E. Sobanski, A. Philipsen, F. McNicholas, H. Caci, I. Mihailescu, I. Manor,b , I. Dobrescu,b , J. Krause,b , J. Fayyad, J.A. Ramos-Quiroga, K. Foeken, F. Rad, M. Adamou, M. Ohlmeier, M. Fitzgerald, M. Gill, M. Lensing, N. Motavalli Mukaddes, P. Brudkiewicza, P. Gustafsson, P. Tani, P. Oswald, P.J. Carpentier, P. De Rossi, R. Delorme, S. Markovsk, Simosk, S. Pallanti, S. Young, S. Bejerot, T. Lehtonen, J. Kustow, U. Müller-Sedgwick, T. Hirvikoski, V. Pironti, Y. Ginsberg, Z. Félegeházy, M.P. Garcia-Portilla, P. Asherson., Updated European Consensus Statement on diagnosis and treatment of adult ADHD; European Psychiatry 56 (2019) 14–34 accepted 3 Nov 2018 193. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E, Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ, Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G, Van

25. Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR., Manifesto for a European research network into Problematic Usage of the Internet. Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. doi: 10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID:30509450 194. Scarpino M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu C, Bastianelli M, Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A., Efficacy of high- frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the MagneTox Study): A study protocol for a randomized placebo-controlled pilot trial. Neurophysiol Clin. 2019 Feb;49(1):1-9. doi: 10.1016/j.neucli.2018.10.002. Epub 2018 Oct 26. PMID:30712533 195. Grassi, G., Pacini, S., Cecchelli, C., Pallanti, S. Enhancing Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder with Transcranic Magnetic Stimulation: A proof of concept. European Neuropsychopharmacology, Volume 28, Issue 6, 2018, Pages 766-767, ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2017.10.008. 196. Grassi G., Makris N., Pallanti S. Olfaction in gambling disorder: an exploratory study. Journal of Behavioral Addictions. ICBA2018 / April 23–25, 2018 / Cologne, Germany. Vol 7., Supplement 1. www.academiai.com 197. Fineberg NA, Dell'Osso B, Albert U, Maina G, Geller D, Carmi L, Sireau N, Walitza S, Grassi G, Pallanti S, Hollander E, Brakoulias V, Menchon JM, Marazziti D, Ioannidis K, Apergis-Schoute A, Stein DJ, Cath DC, Veltman DJ, Van Ameringen M, Fontenelle LF, Shavitt RG, Costa D, Diniz JB, Zohar J., Early intervention for obsessive compulsive disorder: An expert consensus statement. Eur Neuropsychopharmacol. 2019 Feb 14. pii: S0924-977X(19)30159-2. doi: 10.1016/j.euroneuro.2019.02.002. [Epub ahead of print] PMID:30773387 198. HollanderE., Van Ameringen M., Nicolini H., Zohar J., Pallanti S., Nezgoverova V., Fineberg N. E. 01.01 Pharmacological Treatment of resistant OCD. European Neuropsychopharmacology, 2019 vol29, S32, Elsevie 199. Marras A., Gavazzi G., Grassi G., Rathi Y., Mascalchi M., Makris N., Camprodon J.A., Pallanti S. Abstract59: Modulating Inhibitory Control Networks in Gambling Disorder with Theta Burst Stimulation. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. Elsevier. 2019 Mar 1., Vol 12, issue 2, e21. 200. Salerno L., Ramat S., Solari G, Grassi G., Pallanti S. Parkinson’s Disease with Impulse Control Disorders: Higher Prevalence (Frequency) of Symptoms of Attention Deficit Hyperactivity Disorder International Journal of Clinical Psychiatry 2019, 7(1): 1-7 DOI: 10.5923/j.ijcp.20190701.01 201. Burchi E., Makris N., Lee MR., Pallanti S., Hollander E. Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. 2019, Front. Behav. Neurosci. | doi: 10.3389/fnbeh.2019.00070 202. Sacchetti, E. Pallanti, S. Bowden-Jones, H. (2019). Archives of Behavioral Addictions: A new journal for a new era.Archives of Behavioral Addictions, 1(1). doi:10.30435/ABA.01.2019.01

26. 203. Grassi G., Makris N., Pallanti S. Addicted to compulsion: assessing three core dimensions of addiction across obsessive-compulsive disorder and gambling disorder. CNS Spectr. 2019 May 20:1-10. doi: 10.1017/S1092852919000993. [Epub ahead of print] PMID:31106718 204. Dell'Osso B., Vismara M., Benatti B., Cirnigliaro G., Grancini B., Fineberg N., Van Ameringen M., Hollander E., Stein D., Menchon JM., Rodriguez C., Nicolini H., Lanzagorta N., Pallanti S., Grassi G., Lochner C., Marazziti D., Hranov G., Karamustafalioglu O., Hranov L., Zohar J. Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). CNS Spectrums. doi 10.1017/S1092852919001068 Published online: 27 May 2019 205. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Jun 26. pii: S0924-977X (19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub ahead of print] Review. PMID:31255396 206. Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E., Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019 Sep;29(9):1061-1062. doi: 10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. No abstract available. PMID:31371104 207. Kooij JJS, Bijenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, Thome J, Dom G, Kasper S, Nunes FC, Stes S, Mohr P, Leppamaki S, Casas M, Bobes J, Mccarthy JM, Richarte V, Kjems PA, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea- Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkeiwicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young S, Bejerot S, Lehtonen T, Kustow J, Muller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Felegyhazy Z, Garcia-Portilla MP, Asherson P. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry 2019 Feb; 56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16. 208. Pallanti, S. (2018). Meet our New Field Editor. CNS Spectrums, 23(6), 423-423. doi:10.1017/S1092852918001530 209. Pasquini M., Brakoulias V., Pallanti S. Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders. Front Psychiatry. 2020 Feb 25; 11:93. doi: 10.3389/fpsyt.2020.00093. ECollection 2020. 210. Fineberg N.A., Van Ameringen M., Drummond L, Hollander E., Stein D.J. Geller D., Walitza S., Pallanti S., Pellegrini L., Zohar J., Rodriguez C.I., Menchon J.M., Morgado P., Mpavaenda D., Fontenelle L.F., Feusner J.D., Grassi G., Lochner C., Veltman D.J., Sireau N., Carmi L., Adam D., Nicolini H., Dell'Osso B. cu obsessive-

27. compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive. Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Doi.org/10.1016/j.comppsych.2020.152174. 0010-440X/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) 211. Fontenelle LF, Oldenhof E, Eduarda Moreira-de-Oliveira M, Abramowitz JS, Antony MM, Cath D, Carter A, Dougherty D, Ferrão YA, Figee M, Harrison BJ, Hoexter M, Soo Kwon J, Küelz A, Lazaro L, Lochner C, Marazziti D, Mataix-Cols D, McKay D, Miguel EC, Morein-Zamir S, Moritz S, Nestadt G, O'Connor K, Pallanti S, Purdon C, Rauch S, Richter P, Rotge JY, Shavitt RG, Soriano-Mas C, Starcevic V, Stein DJ, Steketee G, Storch EA, Taylor S, van den Heuvel OA, Veale D, Woods DW, Verdejo- Garcia A, Yücel M. A Transdiagnostic perspective of constructs underlying obsessive-compulsive and related idsorders: An international Delphi consensus study. Aust N Z J Psychiatry. 2020 May 4:4867420912327. doi: 10.1177/0004867420912327. [Epub ahead of print] PMID: 32364439 212. Benatti B, Ferrari S, Grancini B, Girone N, Briguglio M, Marazziti D, Mucci F, Dell'Osso L, Gambini O, Demartini B, Tundo A, Necci R, De Berardis D, Galentino R, De Michele S, Albert U, Rigardetto S, Maina G, Grassi G, Pallanti S, Amerio A, Amore M, Priori A, Servello D, Viganò C, Bosi M, Colombo A, Porta M, Dell'Osso B. Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. CNS Spectr. 2020 May 6:1-8. doi: 10.1017/S1092852920001157. [Epub ahead of print] PMID: 32372727 213. Galderisi S, Rucci P, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Bozzatello P, Bucci P, Carpiniello B, Collantoni E, Cuomo A, Dell'Osso L, Di Fabio F, di Giannantonio M, Gibertoni D, Giordano GM, Marchesi C, Monteleone P, Oldani L, Pompili M, Roncone R, Rossi R, Siracusano A, Vita A, Zeppegno P, Maj M; Italian Network for Research on Psychoses*.The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. *Member: Pallanti, S. World Psychiatry. 2020 Feb;19(1):81-91. doi: 10.1002/wps.20700.PMID: 31922687 214. Fontenelle, L. F., Oldenhof, E., Eduarda Moreira-de-Oliveira, M., Abramowitz, J. S., Antony, M. M., Cath, D. C., Carter, A., Dougherty, D., Ferrão, Y. A., Figee, M., Harrison, B. J., Hoexter, M., Soo Kwon, J., Küelz, A., Lazaro, L., Lochner, C., Marazziti, D., Mataix-Cols, D., McKay, D., Miguel, E.C., Morein-Zamir, S., Moritz, S., Nestadt, G., O’Connor, K., Pallanti, S., Purdon, C., Rauch, S., Richte, P., Rotge, J.Y., Shavitt, R.G., Soriano-Mas, C., Stein, D.J., Steketee, G., Sorch, E.A., Taylor, S., Van den Heuvel, O.A., Veale, D., Woods, D.W., Verdejo-Garcia, A., Yucel, M. The International OCRDs Neuroscience Consensus Group (2020). A transdiagnostic perspective of constructs underlying obsessive-compulsive and related disorders: An international Delphi consensus study. Australian & New Zealand Journal of Psychiatry, 54(7), 719-731. https://doi.org/10.1177/0004867420912327 215. Sali, L., Ventura, L., Grazzini, G., Borgherese, A., Delsanto, S., Falchini, M., Mallardi, B., Mantellini, P., Milani, S., Pallanti, S., Zappa M., Mascalchi M. Patients’ experience

28. of screening CT colonography with reduced and full bowel preparation in a randomised trial. Eur Radiol 29, 2457–2464 (2019). https://doi.org/10.1007/s00330- 018-5808-1 216. Fineberg, Naomi A., Hollander, Eric., Pallanti, Stefano., Walitza, Susanne Grünblatt, Ednag,,h,,i; Dell’Osso, Bernardo Mariaj,,k,,l,,m; Albert, Umberton; Geller, Daniel A.o; Brakoulias, Vlasiosp,,q; Janardhan Reddy, Y.C.r; Arumugham, Shyam Sundarr; Shavitt, Roseli G.s; Drummond, Lynnet; Grancini, Benedettab,,j; De Carlo, Verab,,j; Cinosi, Eduardoa,,b; Chamberlain, Samuel R.u,,v; Ioannidis, Konstantinosu,,v; Rodriguez, Carolyn I.k,,w; Garg, Kabirb; Castle, Davidx; Van Ameringen, Michaely,,z; Stein, Dan J.aa; Carmi, Liorbb,,cc; Zohar, Josephbb,,dd; Menchon, Jose M.ee Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders, International Clinical Psychopharmacology: July 2020 - Volume 35 - Issue 4 - p 173-193 doi: 10.1097/YIC.0000000000000314 217. Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. Compr.Psychiatry.2020;100:152184.Doi: 10.1016/j.comppsych.2020.152184 218. Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae [published online ahead of print, 2020 Aug 15]. J Psychiatr Res. 2020;130:215-217. doi: 10.1016/j.jpsychires.2020.08.008 219. Netto, V.D.M., Flores, C., Pallanti, S. Pharmacological Treatment for Comorbid Bipolar Disorder and Obsessive-Compulsive Disorder in Adults, Journal of Psychiatric Practice: September 2020 - Volume 26 - Issue 5 - p 383-393. doi: 10.1097/PRA.0000000000000499 220. Gaur S, Pallanti S. Treatment Outcomes in an Adult Attention Deficit Hyperactivity Disorder Clinic with a Focus on Executive Functioning and Sluggish Cognitive Tempo. Cureus 12(8): e9814. doi: 10.7759/cureus.9814 221. Pallanti, S., Porta, F., Salerno, L., Adult attention deficit hyperactivity disorder in patients with fibromyalgia syndrome: Assessment and disabilities, Journal of Psychiatric Research, 2020, ISSN 0022-3956, https://doi.org/10.1016/j.jpsychires.2020.10.027. (http://www.sciencedirect.com/science/article/pii/S002239562031030X) 222. Castro-Calvo, J., King, D. L., Stein, D. J., Brand, M., Carmi, L., Chamberlain, S. R., Demetrovics, Z., Fineberg, N. A., Rumpf, H.-J., Yücel, M., Achab, S., Ambekar, A., Bahar, N., Blaszczynski, A., Bowden-Jones, H., Carbonell, X., Chan, E. M. L., Ko, C.-H., de Timary, P., Dufour, M., Grall-Bronnec, M., Lee, H. K., Higuchi, S., Jimenez- Murcia, S., Király, O., Kuss, D. J., Long, J., Müller, A., Pallanti, S., Potenza, M. N., Rahimi-Movaghar, A., Saunders, J. B., Schimmenti, A., Lee, S.-Y., Siste, K., Spritzer, D. T., Starcevic, V., Weinstein, A. M., Wölfling, K., and Billieux, J. (2021) Expert appraisal of criteria for assessing gaming disorder: An international Delphi study. Addiction, https://doi.org/10.1111/add.15411.

29. 223. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G., Singh, S. Future Neurology 2020 15:4. 30 Nov 2020 https://doi.org/10.2217/fnl-2020- 0012 224. Micheli, L, Spitoni, S, Di Cesare Mannelli, L, Bilia, AR, Ghelardini, C, Pallanti, S. Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytotherapy Research. 2020; 34: 2331– 2340. https://doi.org/10.1002/ptr.6684 225. Fineberg, N. A., Van Ameringen, M., Drummond, L., Hollander, E., Stein, D. J., Geller, D., Walitza, S., Pallanti, S., Pellegrini, L., Zohar, J., Rodriguez, C. I., Menchon, J. M., Morgado, P., Mpavaenda, D., Fontenelle, L. F., Feusner, J. D., Grassi, G., Lochner, C., Veltman, D. J., Sireau, N., … Dell'Osso, B. (2020). How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. Comprehensive psychiatry, 100, 152174. https://doi.org/10.1016/j.comppsych.2020.152174 226. Uzunova, G., Pallanti, S., Hollander, E. (2021) Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase, International Journal of Psychiatry in Clinical Practice, DOI: 10.1080/13651501.2021.1887264 227. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Bastianelli M, Occupati B, Gori F, Del Vecchio A, Ercolini A, Pascolo S, Cimino V, Meneghin N, Fierini F, D'Anna G, Innocenti M, Ballerini A, Pallanti S, Grippo A, Mannaioni G. A randomised, double- blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. PLoS One. 2021 Nov 16;16(11):e0259860. doi: 10.1371/journal.pone.0259860. PMID: 34784373. 228. Nezgovorova, V., Ferretti, CJ., Pallanti, S., Hollander, E. Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder, Journal of Psychiatric Research,2021, ISSN 0022-3956, https://doi.org/10.1016/j.jpsychires.2021.11.025. 229. Pallanti, S., Marras, A., & Makris, N. (2021). A Research Domain Criteria Approach to Gambling Disorder and Behavioral Addictions: Decision-Making, Response Inhibition, and the Role of Cannabidiol. Frontiers in psychiatry, 12, 634418. https://doi.org/10.3389/fpsyt.2021.634418 230. Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E, Ioannidis K, Pallanti S, Chamberlain SR, Rossell SL, Veale D, Wilhelm S, Van Ameringen M, Dell'Osso B, Menchon JM, Fineberg NA. Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology (Pallanti, S.) Int Clin Psychopharmacol. 2021 Mar 1;36(2):61-75. doi: 10.1097/YIC.0000000000000342. PMID: 33230025; PMCID: PMC7846290.

30. 231. Bentatti, B., Dell’Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, C., Jo, Booil., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti, D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figee, M., Drummond, L., Grant, JE., Denys D., Fontenelle LF., Menchon JM., Zohar, J., Pellegrini, L., Rodriguez, C. Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology, Journal of Psychiatric Research, Volume 140, 2021, Pages 357-363, ISSN 0022-3956, https://doi.org/10.1016/j.jpsychires.2021.05.054. 232. Salerno L., Pallanti S. COVID-19 Related Distress in Gambling Disorder. Frontiers in Psychiatry. VOLUME12. 2021. pp156. https://www.frontiersin.org/article/10.3389/fpsyt.2021.620661. DOI10.3389/fpsyt.2021.620661. ISSN1664-0640 233. Grassi, G., Figee, M., Stratta, P., Rossi, A., & Pallanti, S. Response to Cognitive impulsivity and the behavioral addiction model of obsessive–compulsive disorder: Abramovitch and McKay (2016), Journal of Behavioral Addictions J Behav Addict, 5(3), 398-400. Retrieved Apr 9, 2021, from https://akjournals.com/view/journals/2006/5/3/article-p398.xml 234. Pallanti S, Salerno L. ADHD: the dark side of Eating Disorders. Evidence- based Psychiatric Care 2016;2;24-31, http:/ www.evidence-based- psychiatric-care.org/wp-content/uploads/2016/07/05_pallanti.pdf. ISSN: 2421- 4469 235. Benatti, B., Girone, N., Conti, D., Cafaro, R., Vigano, C., Briguglio, M., Marazziti, D., Mucci, F., Gambini, O., Demartini, B., Tundo, A., Necci, R., De Berardis, D., Galentino, R., De Michele, S., Balestrino, R., Albert U., Rogardetto S., Mania, G., Grassi, G., Pallanti, S., Amerio, A., Aguglia, A., Presta, D., Amore, M., Priori, A., Servello, D., Porta, M., Dell’Osso, B. (2021). Assessing response, remission and treatment resistance in patients with Obsessive-Compulsive Disorder with and without Tic Disorders: results from a multicenter study. CNS Spectrums, 1-22. Doi:10.1017/S109285292100081X 236. Pallanti, S., Marras, A., Dickson, S. L., Adan, R. A. H., Vieta, E., Dell Osso, B., Arango, C., Fusar-Poli, P., Soriano-Mas, C., Carmi, L., Meyer Lindenberg, A., Zohar, J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non- invasive brain stimulation as a new Super-subspecialty, European Neuropsychopharmacology, Volume 52, 2021, Pages 72-83, ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2021.07.002. (https://www.sciencedirect.com/science/article/pii/S0924977X21002728) 237. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander, E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm, S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of

31. Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61– 75. https://doi.org/10.1097/YIC.0000000000000342 238. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G., Singh, S. Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. Future Neurology 2020 15:4. 30 Nov 2020 https://doi.org/10.2217/fnl-2020-0012 239. Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U, Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A, Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH, Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen- Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K, Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J, Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. A Delphi-method- based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2021 Dec 15. doi: 10.1038/s41380-021-01381-x. Epub ahead of print. PMID: 34907394. 240. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander, E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm, S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61– 75. https://doi.org/10.1097/YIC.0000000000000342 241. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non Invasive Brain Stimulation (NIBS) in the era of brain connectivity. Eur Neuropsychopharmacol. 2021 Apr;45 38. doi:10.1016/j.euroneuro.2021.03.004. PMID: 33745763. 242. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Pallanti S., Mannaioni, G. et.al. (2021) A randomised, double-blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine consumption and craving. PLOS ONE 16(11): e0259860. https://doi.org/10.1371/journal.pone.0259860 243. Benatti, B., Girone, N., Conti, D., Cafaro, R., Viganò, C., Briguglio, M., Pallanti S., Dell’Osso, B. et.al. (2021). Assessing response, remission, and treatment resistance in patients with obsessive–compulsive disorder with and without tic disorders: Results from a multicenter study. CNS Spectrums, 1-7. doi:10.1017/S109285292100081X 244. Benatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, Booil Jo, C., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti, D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figee, M., L., Drummond, Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM.,

32. Zohar, J., Pellegrini, L., Rodriguez, CI. Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology, Journal of Psychiatric Research,Volume 140, 2021, Pages 357-363, ISSN 0022-3956, https://doi.org/10.1016/j.jpsychires.2021.05.054. 245. Benatti, B., Ferrari, S., Grancini, B., Girone, N., Briguglio, M., Marazziti, D., Pallanti. S., Dell’Osso, B. et.al. (2021). Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: Results of a multicenter Italian study. CNS Spectrums, 26(4), 354-361. doi:10.1017/S1092852920001157 246. Pallanti, S., Makris, N., Camprodon, J., Rathi, Y., Salerno, L., Marras, A., & Gavazzi, G. (2021). P. 0611 Theta burst stimulation of the pre-supplementary motor area in gambling disorder: preliminary data on gambling severity and clinical global impression. European Neuropsychopharmacology, 53, S449. 247. Van Ameringen, M., Patterson, B., Turna, J., Lethbridge, G., Bergmann, C. G., Lamberti, N., S Pallanti, G Grassi, M Vismara, Umberto Albert, R Gedanke Shavitt, E Hollander, J Feusner, CI Rodriguez, Pedro Morgado Dell’Osso, B. (2022). Obsessive-compulsive disorder during the COVID-19 pandemic. Journal of Psychiatric Research. 248. Benatti B., Girone N., Celebre L., Vismara, M., Hollander, E., Fineberg, NA., Stein, DA., Nicolini, H., Lanzagorta, N., Marazziti, D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu,O., Hranov, L., Figee, M., Drummond, LM., Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM., Zohar, J., Rodriguez, CI., Dell'Osso, B. The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network, Comprehensive Psychiatry, 2022, 152315, ISSN 0010-440X, https://doi.org/10.1016/j.comppsych.2022.152315. PMID: 35483201. (https://www.sciencedirect.com/science/article/pii/S0010440X22000219) 249. Pallanti, S., Ponzio, M., Grassi, E., Vannini, G., Cauli, G. Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study. Children 2022, 9, 755. https://doi.org/10.3390/children9050755 250. Salerno, L., Grassi, E., Makris, N, Pallanti, S. “A Theta Burst Stimulation on Pre- SMA: Proof-of-Concept of Transcranial Magnetic Stimulation in Gambling Disorder”. J Gambl Stud (2022). https://doi.org/10.1007/s10899-022-10129-3 251. Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias Eriksson, Naomi A. Fineberg, Josef Hättenschwiler, Eric Hollander, Hisanobu Kaiya, Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue, Leslie Lim, Vasilios Masdrakis, José M. Menchón, Euripedes C. Miguel, Hans- Jürgen Möller, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu, Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna Vasileva, Zhen Wang & Joseph Zohar (2022) World Federation of Societies of

33. Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive- compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders, The World Journal of Biological Psychiatry, DOI: 10.1080/15622975.2022.2086295 252. Ilenia Pampaloni, Sabina Marriott, Enrico Pessina, Claire Fisher, Anusha Govender, Heba Mohammed, Augusta Chandler, Himanshu Tyagi, Lucy Morris, Stefano Pallanti, The global assessment of OCD, Comprehensive Psychiatry, 2022, 152342, ISSN 0010-440X, https://doi.org/10.1016/j.comppsych.2022.152342.(https://www.sciencedirect.com/s cience/article/pii/S0010440X22000487) Peer-Reviewed Editorials 1. Pallanti S. The anxiety-psychosis spectrum. CNS Spectrums. 2000 Sep;5(9):22. 2. Pallanti S., Transcultural Observations of Obsessive-Compulsive disorder, American Journal of Psychiatry, 165:2, February 2008 3. Pallanti S., Problematic Internet Use: is it more compulsory than rewarding or mood driven? World Psychiatry.2010 Jun;9(2):96-7. 4. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American Journal of Psychiatry. 2008 Feb;165(2):169-70. 5. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood driven? World Psychiatry. 2010 Jun;9(2):96-7. 6. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive- behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation.2014.10.18. 7. Pasquini M., Brakoulias V., Pallanti S. Editorial: Advances in Biological Approaches to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders. Front. Psychiatry 11:93. doi: 10.3389/fpsyt.2020.00093 8. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity, European Neuropsychopharmacology, Elsevier, Editorial. https://doi.org/10.1016/j.euroneuro.2021.03.004 9. Pallanti, S. (2018). Meet our New Field Editor. CNS Spectrums, 23(6), 423-423. doi:10.1017/S1092852918001530 Peer-Reviewed Abstracts 1. Pallanti S., Zuccarini S., Rivelli A., Quercioli L., Pazzagli A. Depth perception in schizophrenia. Biological Psychiatry 35 (9), 637-638. 1994-05-01.

34. 2. Koran L., Sallee F., Pallanti S., Paiva R., Quercioli L. Intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Psychopharmacology Bulletin 32 (3), 466-466. Nov. 1996. 3. Di Russo F., Zaccara G., Pallanti S., Gangemi P., Lori S., Ragazzoni A. Visual event- related potentials in obsessive-compulsive disorders. Electroencephalography and Clinical Neurophysiology 103 (1), 211-211, Jul 1997. 4. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999- 01-01. 5. Russo F., Zaccara G., Ragazzoni A. Pallanti S. Abnormal visual ERPs in obsessive- compulsive deficits in young schizophrenic patients. Journal of Psychophysiology 13 (3), 207-207, 1999-01-01. 6. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological Psychiatry 49 (8), 105S-106S. 2001-04-05. 7. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31. 8. Pallanti S., Quercioli L. Reboxetine in bulimia nervosa: An open study. Biological Psychiatry 49 (8), 105S-106S. 2001-04-05. 9. Quercioli L., Bruscoli M., Pallanti S. P.1.030 Mirtazapine augmentation of citalopram response in OCD patients without comorbid depression: A pilot study. European Neuropsychopharmacology 14, S186, 2004-10-31. 10. Pallanti S., Baker B.R., Chaplin W., Kim S., De Caria C., Bernardi S., Hollander E., Noradrenergic function in pathological gambling. Biological Psychiatry. 2006;59 (8), 32S-32S. 11. Bernardi S., Ramat S., Raglione L., Marini P., Sorbi S., Ammannati F., Pallanti S. Punding after bilateral subthalamic nucleus stimulation in Parkinson’s disease. European Psychiatry 23, S350-S351. 12. Cincotta M., Borgheresi A., Pampaloni I., Giovannelli F., Bernardi S., Cantisani A., Zaccara G., Pallanti S. P27-7 Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation study. Clinical Neurophysiology 121, s265, 2010-20-31. Peer-Reviewed Letters and Commentary 1. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive- compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5. 2. Pallanti S. "Dr. Pallanti Replies." American Journal of Psychiatry, 2000 157(5):840- a–840.

35. 3. Hollander E, Pallanti S. "5-HT1D Function and Repetitive Behaviors." American Journal of Psychiatry, 2001 158(6):972-a–973. 4. Pallanti S, Quercioli L, Hollander E. "Dr. Pallanti and Colleague Reply." American Journal of Psychiatry, 2005 162(2): 400-a–401. 5. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Dr. Faravelli and Associates Reply. American Journal of Psychiatry 150 (9), 1437-1437. 1993-09-01. 6. Grassi G, Figee M, Stratta P, Rossi A, Pallanti S. Response to Cognitive impulsivity and the behavioral addiction model of obsessive-compulsive disorder: Abramovitch and McKay (2016). J Behav Addict. 2016 Sep;5(3):398-400. 7. Koran LM, Faravelli C, Pallanti S. Intravenous clomipramine for obsessive- compulsive disorder. Journal of Clinical Psychopharmacology 1994 Jun;14(3):216-8 8. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive- compulsive disorder. American Journal of Psychiatry. 1999 Nov;156(11):1834-5. 9. Hollander E, Pallanti S. 5-HT(1D) function and repetitive behaviors. American Journal of Psychiatry. 2001 Jun;158(6):972-3. 10. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796. Peer-Reviewed Book Reviews 1. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. American Journal of Psychiatry 1999; 156:1108a-1109. 2. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism. American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01. Book Review 3. Pallanti S. Panic Disorder: Clinical Diagnosis, Management and Mechanism. American Journal of Psychiatry 158(7), 1176-a-1177. 2001-07-01. 4. Pallanti S. Review of perfectionism: theory, research and treatment. American Journal of Psychiatry 2004, vol.161 (8). Other Publications 1. Pallanti S. Vincenzo Chiarugi, 1759-1820. American Journal of Psychiatry. 1996 Jul;153(7):944. 2. Pallanti S. Images in Psychiatry. Ugo Cerletti. 1877-1963 Essay. American Journal of Psychiatry 156.630-630, 1999. 3. Pallanti S. Obsessive-Compulsive Disorder: Theory, Research, and Treatment. American Journal of Psychiatry 1999; 156:1108a-1109

36. 4. Pallanti S., Quercioli L. SSRIs in the treatment of premenstrual dysphoric disorder. Nefazodone: An open trial. European Neuropsychopharmacology 10(S3), 127-128, 2000-09-30 5. Pallanti S. Pathological Gambling, A clinical guide to treatment, American Psychiatric Publishing, 2004, Introduction 6. Pallanti S. From impulse-control disorders toward behavioral addictions. CNS Spectrums. 2006;11(12).921-922. 7. Pallanti S. Unique contributions of brain stimulation to the study of consciousness: where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6. 8. Pallanti S., Book Review: Comprehensive care of schizophrenia: a textbook of clinical management, 2nd edition. American Journal of Psychiatry. 2013 Jan 1;170(1):125-126. 9. Pallanti S., Strategies for Treatment Resistant OCD, Psychiatric Times. 2014. Book Chapters 1. Pallanti S., Rossi L., De Palma G., Checchi M., Muscas C., Faravelli C. Electroencephalogram mapping in sodium lactate-induced panic attacks: Preliminary results. Imaging of the Brain in Psychiatry and Related Fields, pp 281-284, Edited by K. Maurer, Springer, 1993 2. Current and Experimental Therapeutics of Obsessive Compulsive Disorders, pp 1647 – 1664, Neuropsychopharmacology: The Fifth Generation of Progress, An Official Publication of the American College of Neuropsychopharmacology, Edited by K.L. Davis, D. Charney, J.T. Coyle and C. Nemeroff, Lippincott/Williams and Wilkins, 2002 3. Psychobiology of Impulse Control Disorders Not Otherwise Specified (NOS), pp 1315 – 1329, Biological Psychiatry, Edited by H. D’Haenen, J.A. den Boer, P. Willner, John Wiley & Sons Ltd., 2002 4. Sood E, Pallanti S, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. Essential Psychopharmacology, pp 157-169, Edited by R. Murray, Cambridge University Press, 2002 5. Pharmacological Treatments, pp 189 – 200, Pathological Gambling: A Clinical Guide to Treatment, Edited by J. E. Grant, M. Potenza, American Psychiatric Publishing, 2004 6. Pathological Gambling, pp 251 – 289, Clinical Manual of Impulse Control Disorders, Edited by E. Hollander, D. Stein, American Psychiatric Publishing, 2006 7. Approaches to treatment resistance, pp. 99-117, Obsessive Compulsive Disorder: Current Science and Clinical Practice, Edited by J. Zohar, John Wiley & Sons, LTD, 2012 8. Positron Emission Tomography. Edited by Miscaglia, S. pp.177 – 188. Chapter 7, Santoro D., Pallanti S. Pathological Gambling: PET Studies. December 18th 2013

37. DOI: 10.5772/57537 ISBN: 978-953-51-1213-6 eBook (PDF) ISBN: 978-953-51- 7188-1 Copyright year: 2013 9. Pharmacological treatment of Autism Spectrum Disorders, pp. 151 – 166, Autism Spectrum Disorders- Phenotypes, Mechanisms and treatment, Edited by M. Leboyer, P. Chaste, Karger Medical and Scientific Publishers, 2015 10.New Technologies in Autism: Non-invasive Brain Stimulation, Autism Spectrum Disorders, Enticott PG, Pallanti S, Ring R, Pascual-Leone A, Hollander E., Edited by E. Hollander, D. Fein, P.J. Hagerman. Karger Medical and Scientific Publishers, 2017 [in press] 11.Incompleteness and Harm Avoidance in OCD, pp. Obsessive-Compulsive Disorder – Phenomenology, Pathophysiology and Treatment, Pallanti S, Barns J, Pittenger C, Eisen, J., Edited by Pittenger C. Oxford University Press, 2017 12.Handbook of Psychiatry and Behavioral Health, pp. 73 – 81, Malingering Fictitious Disorder: The Assessment of Competence and (Capacity) and Forensic Aspects., Organs and Living Donars, and Trasplantation; The so-called “Biological Testament”. Carocci Editori Roma, March 2020 13.Consultant to: Long version of the interdisciplinary evidence- and consensusbased (S3) guideline “Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults” AWMF Registration No. 028-045. Published at AWMF online. Association of Analytical Child and Adolescent Psychotherapists in Germany (Vereinigung Analytischer Kinder- u. Jugendlichen-Psychotherapeuten in Deutschland e. V., VAKJP) 14.Salerno L, Gaur S, Grassi G, Pallanti S. Neuromodulation in Attention- Deficit/Hyperactivity Disorder: Toward a Precision Psychiatry Approach Chapter in Bernardo Dell'Osso and Giorgio Di Lorenzo (Eds): Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences, 978-3-030-43355- 0, 479307_1_En, (9) Books 1. Pallanti S., Vivere con le Voci, Vivere nel Silenzio, (Live with Voices, Live in Silence, La nuova Italia Scientifica (1996) 2. Fossi G., Pallanti S., Manuale di Psichiatria (Manual of Psychiatry), Casa Editrice Ambrosiana, Milano (1993) 3. Pallanti S., Koran L. M., Treatment of OCD Resistant Patients, Airon (2003) 4. Pallanti S., Bruscoli M., Le Emergenze Psichiatriche in Medicina, (Psychiatric Emergency in Medicine) Lippincott /Williams and Wilkins, (2006) sold exclusively by Innova Pharma SpA, Milano 5. Fossi G., Pallanti S., Psichiatria Elementare (Elementary Psychiatry), La Nuova Italia Scientifica S.p.A. Roma. First edition 1993, 6th edition 2008 6. Pallanti, S. and Lauriello, J., Clinical Manual for Schizophrenia, Edited by B. Hales, American Psychiatric Publishing. (2010)

Prof. Stefano Pallanti - CV 18 Agosto 2022

You are reading a preview.

Check these out next

Prof. Stefano Pallanti - CV 18 Agosto 2022

More Related Content

Similar to Prof. Stefano Pallanti - CV 18 Agosto 2022 (20)

More from Istituto di Neuroscienze del Prof. Stefano Pallanti (15)

Recently uploaded (20)